Literature DB >> 30257080

Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.

Thierry Q Mentzel1,2,3, René van der Snoek4, Ritsaert Lieverse2, Margreet Oorschot4, Wolfgang Viechtbauer2, Oswald Bloemen2,3, Peter N van Harten2,3.   

Abstract

OBJECTIVE: Tardive dyskinesia (TD) is an antipsychotic-induced movement disorder that typically occurs after long-term exposure to antipsychotic drugs. There is evidence that switching to clozapine reduces TD. This meta-analysis reviews the effect of switching to clozapine on the severity of TD. DATA SOURCES: The PubMed, PsycINFO, and Embase databases were searched for clozapine, tardive dyskinesia, and related keywords. The search was restricted to articles written in English and Dutch, and it was last updated on October 13, 2015. STUDY SELECTION: Sixteen studies were included in the meta-analysis. Inclusion criteria were a diagnosis of schizophrenia or a related disorder, a switch to clozapine monotherapy, and reports of scores on a TD rating scale before and after the switch to clozapine. DATA EXTRACTION: Two independent investigators extracted the data. Data were converted to standardized mean change scores and analyzed in a random-effects model.
RESULTS: A random-effects model showed that the overall effect of switching to clozapine was a significant reduction in TD (npatients = 1,060, d = -0.40, P < .01), especially in the 4 studies that investigated the severity of TD as a primary outcome (npatients = 48, d = -2.56, P = .02).
CONCLUSIONS: The overall results show that clozapine treatment can yield a slight reduction in TD. The severity of TD was reduced greatly in patients with moderate to severe TD. In patients with minimal to mild TD, switching to clozapine seldom worsens TD and a trend toward reduction is seen. These results support that a switch to clozapine should be considered for patients with moderate to severe TD and/or patients who experience substantial discomfort due to TD. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30257080     DOI: 10.4088/JCP.17r11852

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

2.  Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Authors:  Sarah M Debrey; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

3.  Perspectives in Psychopharmacology.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 4.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

5.  Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis.

Authors:  Remiko Kobayashi; Yasunori Oda; Ryunosuke Hayatsu; Nozomi Ohki; Misa Akutsu; Takahiro Oiwa; Hideki Komatsu; Tomihisa Niitsu; Tsuyoshi Sasaki; Masaomi Iyo
Journal:  SAGE Open Med Case Rep       Date:  2020-06-07

Review 6.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.